Biotech
Alnylam Pharmaceuticals
Alnylam Pharmaceuticals raises $360M Convertible Note at $25B valuation
$360M
Total Raised
Convertible Note
Latest Round
2002
Founded
2000+
Employees
675 West Kendall Street, Cambridge, MA 02142
1 min read
Quick Facts
Valuation
$25B
Latest Round Size
$360M
Latest Round Date
May 2024
Alnylam Pharmaceuticals: Convertible Note Funding Round
Alnylam Pharmaceuticals has successfully raised $360M in Convertible Note funding, reaching a valuation of $25B.
Company Overview
RNAi therapeutics
Funding Details
The Convertible Note round was led by Millennium Partners, with participation from Polaris Partners, Temasek Holdings.
Company Information
- Headquarters: 675 West Kendall Street, Cambridge, MA 02142
- Founded: 2002
- Employees: 2000+
- Category: Biotech
Investment
Alnylam Pharmaceuticals plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- Millennium Partners: Verified investor in Convertible Note
- Polaris Partners: Verified investor in Convertible Note
- Temasek Holdings: Verified investor in Convertible Note
Key Investors
Millennium Partners
Lead Investor
Verified investor in Convertible Note
Polaris Partners
Investor
Verified investor in Convertible Note
Temasek Holdings
Investor
Verified investor in Convertible Note
About the Author
Editorial Team
Curated funding news from verified sources
Related Company Reports
Biotech
Orna Therapeutics
Orna Therapeutics Raises $251M Series B
Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases
Emma Rodriguez
Oct 23, 2025
0 min readβ’$251M Series B
Biotech
Forge Biologics
Forge Biologics Raises $120M Series C
Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines
Sarah Kim
Oct 23, 2025
0 min readβ’$120M Series C
Biotech
Vir Biotechnology
Vir Biotechnology Raises $250M
Clinical-stage immunology company developing treatments for infectious diseases including COVID-19, hepatitis B, and influenza
Sarah Kim
Oct 23, 2025
0 min readβ’$250M